Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ: LGND · Real-Time Price · USD
103.27
-3.08 (-2.90%)
May 6, 2025, 4:00 PM EDT - Market closed
-2.90%
Market Cap 1.99B
Revenue (ttm) 167.13M
Net Income (ttm) -4.03M
Shares Out 19.28M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE 38.13
Dividend n/a
Ex-Dividend Date n/a
Volume 95,800
Open 105.98
Previous Close 106.35
Day's Range 103.27 - 105.98
52-Week Range 72.61 - 129.90
Beta 0.76
Analysts Strong Buy
Price Target 144.67 (+40.09%)
Earnings Date May 8, 2025

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 18, 1992
Employees 68
Stock Exchange NASDAQ
Ticker Symbol LGND
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price forecast is $144.67, which is an increase of 40.09% from the latest price.

Price Target
$144.67
(40.09% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ligand to Participate in May Investor Conferences

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...

5 days ago - GlobeNewsWire

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the ...

12 days ago - GlobeNewsWire

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug a...

19 days ago - GlobeNewsWire

Ligand to Participate in March Investor Conferences

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza w...

2 months ago - GlobeNewsWire

Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysi...

2 months ago - Seeking Alpha

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6...

2 months ago - GlobeNewsWire

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors...

Other symbols: XOMA
2 months ago - GlobeNewsWire

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

JUPITER, Fla.--(BUSINESS WIRE)--Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025.

2 months ago - Business Wire

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

JUPITER, Fla.--(BUSINESS WIRE)--Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

3 months ago - Business Wire

Looking Back On Ligand Pharmaceuticals

Today, I am circling back to Ligand Pharmaceuticals for the first time since late 2023. The stock has had a nice run in recent months and management has a solid game plan to grow revenues at north of ...

3 months ago - Seeking Alpha

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

4 months ago - Seeking Alpha

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Dav...

5 months ago - Business Wire

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

I continue to rate Ligand Pharmaceuticals stock as a "Buy" citing strong liquidity and a clean balance sheet. Its Q3 2024 earnings report beat on the top and bottom lines raising prior guidance, reinf...

5 months ago - Seeking Alpha

Ligand to Present at Stifel 2024 Healthcare Conference

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the...

6 months ago - Business Wire

Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis...

6 months ago - Seeking Alpha

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance.

6 months ago - Business Wire

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m....

6 months ago - Business Wire

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial mar...

6 months ago - Business Wire

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. F...

Other symbols: TVTX
8 months ago - Business Wire

CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030

Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Global CD40 Ligand Market by Type (Monoclonal Antibody, Polyclonal Antibody), Application (Autoimmune Disease Treatment, Immunotherapy, Vaccine Developme...

8 months ago - GlobeNewsWire

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the...

9 months ago - Business Wire

Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Todd Davis - CEO Tavo Espinoza - CFO Paul Hadden - Senior Vice Presid...

9 months ago - Seeking Alpha

Ligand Reports Second Quarter 2024 Financial Results

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast...

9 months ago - Business Wire

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Ligand Pharmaceuticals has seen over a 50% increase in share value since its Q1 earnings report. Recent positive developments include new deals, regulatory successes, and raising 2024 guidance. A new ...

10 months ago - Seeking Alpha

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there a...

10 months ago - Accesswire